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I-Aryl-4-oxo-4.5.6.7-tctrahydroindoles (1-16) have been synthe-
sised by the condensation of cyclohexane-I.3-dione-2-acetic esters 
with anilines, Hydrolysis of 1-16 alTords the corresponding acids(l7-
32). bearing resemblance to the nonsteroidal antiinl1~mmatory 
agent. diclofenac 38, Some members of both classes show 
antiinllammatory activity in the carragenin oedema test and 
analgesic activity in mouse writhing test. but are devoid of 
prostaglandin synthetase inhibiting property. Among these. 1-
carboxymethylene-2-{ 4-t rill uoromethyla n ilino )-I-cyclo hexen-6-one 
(20) has marginal activity in the chronic adjuvant arthritis model of. 
inllammation. 
The phenomenal success of diclofenac (38) as a 
nonsteroidal antiinflammatory agent 1 and the recent 
publication of a Japanese patent 2 for a new process for 
its manufacture prompts us to record results of a very 
similar project we had recently completed. 
As part of our exercises to build heterocycles onto 
cyclohexane-l,3-diones3.4 for diverse biological 
activities 5 -7, we synthesised several 4coxo-4,5,6,7-
tetrahydrooxindoles (1-16) in 40-60% yield by the 
reaction of anilines with acetic acid esters (35-37) which 
were available from the knownM alkylation of 
'cyclohexane-l,3-diones (33 and 34) by ethyl (X-
bromoacetate of (X-bromopropionate, respectively. 
Exposure of 1-16 to hot aq sodium bicarbonate led to 
the corresponding, soluble sodium salts of acids (17-
32) in yields around 80%. Physical data for the two 
series are presented in Tables 1 and 2. All new 
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compounds were properly characteriz~d by microa-
nalytical data (C.H,N) and structures were supported 
by spectral data. 
It was our initial objective to aromatise the 2,6-
dichlorophenyl derivative 25 to diclofenac, but we 
were sidetracked by the observation of some 
antiinflammatory-analgesic actIVities for a few 
members of the study. The screening consisted of the 
following routine tests: Prostaglandin synthetase 
inhibition in vitro; and inhibition of carragenin foot 
oedema in rats and inhibition of writhing syndrome 
induced by phenyl-p-benzoquinone in mouse. A very 
small number of active compounds were also subjected 
to the' following tests: Leukotriene B4 inhibition in 
vitro; and arachidonic acid lung embolism and 
adjuvant, arthritis in rabbit. These tests were carried 
out according to routine protocols1.9.1O. 
Table 1 ~ l-Aryl-4-oxo-4,5,6, 7-tetrahydrooxindoles (1-16) 
Compd R Mol. formula Crystallised m.p. 
from· °C 
H C14H13N02 A+C 136-38 
2 3-CF3 C'SH'2 F 3N0 2 F+D 132-34 
3 4-CI C '4H '2C1N02 F+C+D 118-20 
4 4-CF3 C, sH 12F 3N0 2 F+C 130-31 
S 4-Me C,sH,sN02 F+C 136-38 
6 4-F C'4H '2FN02 F+C 156-58 
7 4-0Me C,sH,sN03 B+C 98-100 
8 2.3-DiMe C'6H '7 N0 2 F+C+D 123-25 
9 2.6-DiCl C'4H "C1 2N02 F+D 146c~8 
10 H C'6H I7N0 2 F+D 182-84 
II 2-Me C'7H 19N0 2 F+C+D 140-42 
12 3-CF3 C 17H'6F 3N0 2 F+D 130-32 
13 4-F C'6H '6FN02 F+C 144-46 
14 2.3·DiMe C,.H 2,N02 F+C+D 154-58 
IS 3-CFJ gum 
16 4-F C'SH'4FN02 F+D 158-60 
.Solvents for crystallisation: A-Chloroform; B-ethanol; C-ether; D-
hexane; E-methanol; F-methylenechloride 
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Table 2-Carboxymethylene-2-anilino-l-cyclohexen-
6-ones (17-32) 
Compel R Mol. formula Crystallised m.p. 
fromo °e 
17 H CI4H"N03 F+E+C 180-82 
18 3-CF3 C 1sH l4F 3N03 F+E+C 172-74 
19 4-CI Cl4Hl4ClN03 F+C 140-42 
20 4-'CF3 ClsHl4F3N03 F+E+C 148·50 
21 4-Me C 1sH 17 N03 F+E+C 150·52 
22 4-F Cl4Hl4FN03 F+E+C 132·34 
23 4-0Me C,sH 17N04 F+E+C 146-48 
24 2,3-DiMe C'6H '9N03 F+C 138-40 
2S 2,6-DiCI C'4H 13Cl 2N03 F+E+C 180-82 
26 H C'6H '9N03 C 200·1 
27 2-Me C'7H 21 N03 F+C 150-52 
28 3-CF3 C'7H 18 F3NOJ F+E+C 152-55 
29 4-F C I6H,sFN03 F+E+C 205·8 
30 2,3-DiMe C 18H 23N03 F+C+D 152·57 
31 3-CF3 C;6H I6F3N03 F+E+C 128·30 
32 4-F ClsHl6FN03 F+C 117·20 
·For solvents of crystallisation see Table 1. 
Among the perhydroxindoles, compound 6 was 
quite potent in the carrag~nin oedema test (ED40 30 
mg/kg p.o. ~phenylbutazone) and in the arachidonic 
acid embolism test. It had peripheral analgesic activity 
in mouse writhing syndrome test (ED 50 40 mg/kg p.o.). 
On the other hand, it had no in vitro activity in the 
prostaglandin (upto 3000 nona mol/litre) or 
leukotriene assay. Although these properties could 
signify an interesting mode of action for 6', lack of 
activity in the chronic adjuvant arthritis model of 
inflammation even at 200 mg/kg p.o. rendered it 
uninteresting as a candidate drug. Among the acetic 
acids, the 2,6-dichloroanilino derivative 25 was only 
one-fiftieth as active in the carragenin oedema test 
(ED40> 100 mg/kg p.o) as compared to diclofenac 
(38) (ED40~2 mg/kg p.o.). Compound 18 was more 
active than 25, but had no analgesic activity or activity 
in the adjuvant arthritis test. The 4-trifluoromethyl-
anilino acid (20) had moderate activity in the 
carragenin oedema test (ED40~20_mg/kg p.o.) and 
good analgesic activity in the mouse writhing test 
(EDso ~ 10 mg/kg p.o.) but had a flat dose-response 
curve in both the tests. Its inactivity in the in vitro 
prostaglandin synthesis test upto 3000 nonamol/litre 
in contrast to highly potent 38 (lC 50 1.2 nonamol/litre) 
should have qualified it tOr further development, since 
it could signify an interesting mode of action'. 
However, in the critical adjuvant arthritis model of 
inflammation, 20 had only very weak activity (ED40 
> 100 mg/kgp.o.) compared to 38 (ED40 0.5 mg/kg 
p.o.), thus disallowing any serious interest in the 
compound. 
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2-Carbethoxymethylenecyclohexane-I,3-diones 
2-Carbethoxymethylenecyclohexane-I,3-dione (35) 
was prepared by the action of ethyl bromoacetate on 
cyclohexane-l ,3-diones. 
Compound 36 (m.p.) 105-8°; from methylene 
chloride-ether) and 37 (m.p. 98-100°; from methylene 
chloride-ether) were prepared similarly. 
4-0 xo-4,5,6, 7-tetrahydrooxindoles (1-16) 
A mixture of 36 (7 g), aniline (3.5 g) and acetic acid 
(35ml) was heated under reflux for 16hr. Acetic acid 
was removed in vacuo and the residue triturated with 
water to afford 1. 
Similarly were prepared 2-16(yield 30-601.,). In some 
cases gums were obtained which were chroma tog-
raphed over silica gel using chloroform containing 2% 
methanol. The first fractions gave the. required 
compounds and the latter ones gave acetanilides. The 
physical data and solvent of recrystallisation for 1-16 
are given in Table 1. 
l-Carboxymethylene-2-anilino-l-cyclohexen-6-ones 
(17-32) 
A mix ture of 1 (6 g), ethanol (15 ml) and sa tura ted aq 
. sodium bicarbonate (160 ml) was boiled under reflux 
for 5 hr after which it was cooled and extracted with 
ether. The organic layer was removed and the aqueous 
layer carefully acidified to pH 4-5 with cone. 
hydrochloric acid to obtain 17. 
Compounds 18-32 were prepared similarly. The 
physical data and solvent of recrystallisation for 
compounds 17-32 are given in Table 2. 
The authors wish to thank the CIBA-GEIGY, 
Basel, for making available screening results of 
compounds of this study. 
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